Dainippon Sumitomo expects hit from generic amlodipine
This article was originally published in Scrip
Dainippon Sumitomo Pharma(DSP) expects the launch of a large number of generic amlodipine products in Japan in July to hit its branded version and top product Amlodin, sales of which it forecasts will slide by 10% to ¥57.0 billion ($530.2 million) this fiscal year.
You may also be interested in...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.